Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaoding Xu

Showing results (11-20 of 98) with videos related to

Pageof 10
Sort By:
Frontiers in Immunology|January 9, 2023
Advances in pathogenesis and nanoparticles (NPs)-mediated treatment of psoriasisQian Shen, Rong Liu, Shiyu Tan, et al.
Carcinogenesis|July 6, 2022
HMGN4 plays a key role in STAT3-mediated oncogenesis of triple-negative breast cancerJiahui Mou, Xiaoding Xu, Feifei Wang, et al.
Biomaterials|November 26, 2021
Reduction-responsive RNAi nanoplatform to reprogram tumor lipid metabolism and repolarize macrophage for combination pancreatic cancer therapyShuwen Cao, Phei Er Saw, Qian Shen, et al.
Chemical Communications (Cambridge, England)|November 6, 2019
A polyprodrug-based nanoplatform for cisplatin prodrug delivery and combination cancer therapyChunhao Lin, Yiran Tao, Phei Er Saw, et al.
Frontiers in Pharmacology|November 3, 2018
Tumor-Associated Fibronectin Targeted Liposomal Nanoplatform for Cyclophilin A siRNA Delivery and Targeted Malignant Glioblastoma TherapyPhei Er Saw, Ao Zhang, Yan Nie, et al.
Acta Pharmaceutica Sinica. B|March 27, 2023
Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapyZhihui Dong, Zhuoshan Huang, Senlin Li, et al.
Nano Letters|July 5, 2024
Antibody-Decorated Nanoplatform to Reprogram Macrophage and Block Immune Checkpoint LSECtin for Effective Cancer ImmunotherapyRui Xu, Xiangya Liu, Yuxuan Zhang, et al.
Nano Letters|August 6, 2019
Stimuli-Responsive Polymer-Prodrug Hybrid Nanoplatform for Multistage siRNA Delivery and Combination Cancer TherapyPhei Er Saw, Herui Yao, Chunhao Lin, et al.
Angewandte Chemie (International Ed. in English)|February 5, 2020
Nanostructure Engineering by Simple Tuning of Lipid CombinationsPhei Er Saw, Xiaoding Xu, Meng Zhang, et al.
Pharmacological Research|March 19, 2021
New PCSK9 inhibitor miR-552-3p reduces LDL-C via enhancing LDLR in high fat diet-fed miceNingning Ma, Lei Fan, Yunxia Dong, et al.
Pageof 10

Showing results (11-20 of 98) with videos related to

Sort By:
Pageof 10
Frontiers in Immunology|January 9, 2023
Advances in pathogenesis and nanoparticles (NPs)-mediated treatment of psoriasisQian Shen, Rong Liu, Shiyu Tan, et al.
Carcinogenesis|July 6, 2022
HMGN4 plays a key role in STAT3-mediated oncogenesis of triple-negative breast cancerJiahui Mou, Xiaoding Xu, Feifei Wang, et al.
Biomaterials|November 26, 2021
Reduction-responsive RNAi nanoplatform to reprogram tumor lipid metabolism and repolarize macrophage for combination pancreatic cancer therapyShuwen Cao, Phei Er Saw, Qian Shen, et al.
Chemical Communications (Cambridge, England)|November 6, 2019
A polyprodrug-based nanoplatform for cisplatin prodrug delivery and combination cancer therapyChunhao Lin, Yiran Tao, Phei Er Saw, et al.
Frontiers in Pharmacology|November 3, 2018
Tumor-Associated Fibronectin Targeted Liposomal Nanoplatform for Cyclophilin A siRNA Delivery and Targeted Malignant Glioblastoma TherapyPhei Er Saw, Ao Zhang, Yan Nie, et al.
Acta Pharmaceutica Sinica. B|March 27, 2023
Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapyZhihui Dong, Zhuoshan Huang, Senlin Li, et al.
Nano Letters|July 5, 2024
Antibody-Decorated Nanoplatform to Reprogram Macrophage and Block Immune Checkpoint LSECtin for Effective Cancer ImmunotherapyRui Xu, Xiangya Liu, Yuxuan Zhang, et al.
Nano Letters|August 6, 2019
Stimuli-Responsive Polymer-Prodrug Hybrid Nanoplatform for Multistage siRNA Delivery and Combination Cancer TherapyPhei Er Saw, Herui Yao, Chunhao Lin, et al.
Angewandte Chemie (International Ed. in English)|February 5, 2020
Nanostructure Engineering by Simple Tuning of Lipid CombinationsPhei Er Saw, Xiaoding Xu, Meng Zhang, et al.
Pharmacological Research|March 19, 2021
New PCSK9 inhibitor miR-552-3p reduces LDL-C via enhancing LDLR in high fat diet-fed miceNingning Ma, Lei Fan, Yunxia Dong, et al.
Pageof 10